Segantii Capital Management’s Cytokinetics CYTK Stock Holding History

Segantii Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$14.7M	Buy	+210,000	New	+$16.2M	0.96%	19

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Segantii Capital Management's CYTK Position: Q1 2024 in Review

Segantii Capital Management opened a new position in Cytokinetics (CYTK) in Q1 2024: 210,000 shares worth $14.7M. The stake represents 0.96% of the portfolio and ranks #19 among its holdings.

390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Segantii Capital Management held 210,000 shares of Cytokinetics worth $14.7M as of Q1 2024.
Cytokinetics was a new Segantii Capital Management position in Q1 2024.
Cytokinetics made up 0.96% of Segantii Capital Management's portfolio in Q1 2024, its #19 holding.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Segantii Capital Management's 13F filing for Q1 2024, filed 14 May 2024.